A5080459428- Pancreatic function and diabetes
- Diabetes Management and Research
- Diabetes and associated disorders
- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diet, Metabolism, and Disease
- Diet and metabolism studies
- Pharmacology and Obesity Treatment
- Adipose Tissue and Metabolism
- Diabetes Management and Education
- Adipokines, Inflammation, and Metabolic Diseases
- Nutritional Studies and Diet
- Endoplasmic Reticulum Stress and Disease
- Liver Disease Diagnosis and Treatment
- Blood Pressure and Hypertension Studies
- Cardiovascular Function and Risk Factors
- Archaeological and Historical Studies
- Mitochondrial Function and Pathology
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health and Lifestyle Studies
- Pancreatitis Pathology and Treatment
- Peroxisome Proliferator-Activated Receptors
- Fatty Acid Research and Health
- Cannabis and Cannabinoid Research
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2012-2022
Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas
2012-2022
Hospital Clínic de Barcelona
2010-2022
Universitat Oberta de Catalunya
2019-2022
Instituto de Salud Carlos III
2019-2022
Universitat de Barcelona
2010-2021
Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition
2013
Centro de Investigación Biomédica en Red
2012
Hospital Universitari de Vic
1997-2010
Institut d'Investigacions Biomèdiques de Barcelona
2009
Microalbuminuria and hypertension are risk factors for the development of diabetic nephropathy. Blockade renin-angiotensin system reduces progression to nephropathy in type 1 patients, whereas similar data lacking hypertensive 2 subjects. We evaluated renoprotective effect an angiotensin II receptor antagonist, irbesartan, patients with microalbuminuria.Five hundred ninety microalbuminuria were enrolled this multinational, randomised, double-blind, placebo-controlled study irbesartan 150...
The worldwide explosive increase in type 2 diabetes mellitus and its cardiovascular morbidity are becoming major health concerns.To evaluate the effect of decreasing postprandial hyperglycemia with acarbose, an alpha-glucosidase inhibitor, on risk disease hypertension patients impaired glucose tolerance (IGT).International, multicenter double-blind, placebo-controlled, randomized trial, undertaken hospitals Canada, Germany, Austria, Norway, Denmark, Sweden, Finland, Israel, Spain from July...
The Di@bet.es Study is the first national study in Spain to examine prevalence of diabetes and impaired glucose regulation. A population-based, cross-sectional, cluster sampling was carried out, with target population being entire Spanish population. Five thousand seventy-two participants 100 clusters (health centres or equivalent each region) were randomly selected a probability proportional size. Participation rate 55.8%. variables clinical demographic structured survey, lifestyle physical...
A recent meta-analysis raised concern regarding an increased risk of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment type 2 diabetes.We conducted unplanned interim analysis a randomized, multicenter, open-label, noninferiority trial involving 4447 patients diabetes who had inadequate glycemic control while receiving metformin or sulfonylurea, in which 2220 were assigned to receive add-on (rosiglitazone group), 2227 combination plus...
OBJECTIVE—To assess the 12- and 52-week efficacy of dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment. RESEARCH DESIGN AND METHODS—We conducted a 12-week, randomized, double-blind, placebo-controlled trial 107 40-week extension those completing core study agreeing, together investigator, to extend treatment 1 year. Placebo (n = 51) or (50 mg once daily, n 56) was added ongoing (1,500–3,000 mg/day). HbA1c fasting plasma...
Large prospective studies have demonstrated that optimum glycemic control is not routinely achieved in clinical practice. Barriers to optimal insulin therapy include hypoglycemia, weight gain, and suboptimal initiation dose titration. This study compared two treatment algorithms for glargine titration: algorithm 1 (investigator led) versus 2 (performed by subjects).A prospective, multicenter (n = 611), multinational 59), open-label, 24-week randomized trial 4,961 (algorithm 1, n 2,493; 2,...
We report the characterization of a new insulinotropic compound, 4-hydroxyisoleucine. This amino acid has been extracted and purified from fenugreek seeds, which are known in traditional medicine for their antidiabetic properties. 4-Hydroxyisoleucine increases glucose-induced insulin release, concentration range 100 μmol/l to 1 mmol/l, through direct effect on isolated islets Langerhans both rats humans. The stimulating 4-hydroxyisoleucine was strictly glucose dependent; indeed, ineffective...
This study was designed to test the efficacy and safety of low-dose rosiglitazone, a potent, insulin-sensitizing thiazolidinedione, in combination with sulphonylurea Type 2 diabetic patients.For intention-to-treat analysis, 574 patients (59% male, mean age 61 years) were available, randomized receive 26 weeks twice-daily placebo (n = 192), rosiglitazone 1 mg 199) or 183) addition existing treatment gliclazide (47.6% patients), glibenclamide (41.8%) glipizide (9.4%) (two taking carbutamide...
Abstract Aims The goal of the study was to determine whether continuous subcutaneous insulin infusion (CSII) differs from a multiple daily injection (MDI) regimen based on neutral protamine hagedorn (NPH) as basal with respect glycaemic control and quality life in people Type 1 diabetes. Methods 5‐Nations trial randomized, controlled, crossover conducted 11 European centres. Two hundred seventy‐two patients were treated CSII or MDI during 2‐month run‐in period followed by 6‐month treatment...
AimsThiazolidinediones are insulin sensitizers, and associated with fluid retention increased risk of heart failure (HF) in people type 2 diabetes. We assessed fatal non-fatal HF events their outcome, identified predictors the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes Regulation glycaemia Diabetes) trial population.
To compare the efficacy, safety and tolerability of linagliptin or placebo administered for 24 weeks in combination with pioglitazone patients type 2 diabetes mellitus (T2DM) exhibiting insufficient glycaemic control (HbA1c 7.5-11.0%).Patients were randomized to receive initial 30 mg plus 5 (n = 259) 130), all once daily. The primary endpoint was change from baseline HbA1c after treatment, adjusted prior antidiabetes medication.After mean (±s.e.) -1.06% (±0.06), compared -0.56% (±0.09)...
Three novel human insulin-releasing cell lines designated 1.1B4, 1.4E7, and 1.1E7 were generated by electrofusion of freshly isolated pancreatic beta cells the immortal PANC-1 epithelial line. Functional studies demonstrated glucose sensitivity responsiveness to known modulators insulin secretion. Western blot, RT-PCR, immunohistochemistry showed expression major genes involved in proinsulin processing stimulus-secretion pathway including PC1/3, PC2, GLUT-1, glucokinase, K-ATP channel...
Nutrition therapy is the cornerstone of treating diabetes mellitus. The inclusion fish (particularly oily fish) at least two times per week recommended by current international dietary guidelines for type 2 diabetes. In contrast to a large number human studies examining effects on different cardiovascular risk factors, little research this topic available in patients with aims pilot study were investigate sardine-enriched diet metabolic control, adiponectin, inflammatory markers, erythrocyte...
Our aim was to determine the incidence of type 2 diabetes mellitus in a nation-wide population based cohort from Spain (di@bet.es study). The target Spanish population. In total 5072 people older than 18 years,were randomly selected all over Spain). Socio-demographic and clinical data, survey on habits (physical activity food consumption) weight, height, waist, hip blood pressure were recorder. A fasting draw an oral glucose tolerance test performed. Determinations serum made. follow-up same...
CD14, a GPI-linked membrane protein, is component of the lipopolysaccharide (LPS) receptor complex, one pattern-recognizing receptors (PRR) expressed by myeloid lineage cells. Here we report that functionally linked toll-like molecules, TLR2 and TLR4, associated molecule MD-2 are in endocrine cells human pancreatic islets. CD14 expression islets was determined immunofluorescence staining tissue sections primary cultures, confirmed flow cytometry dispersed normal SV40-transformed islet...
OBJECTIVE—Human islet amyloid polypeptide (hIAPP) aggregation plays a major role in the development of amyloidosis type 2 diabetes. It is known that extracellular hIAPP oligomers are toxic to pancreatic β-cells and associated with apoptosis. We therefore investigated molecular mechanism by which mediates β-cell RESEARCH DESIGN AND METHODS—MIN6 cells primary cultures human islets were treated freshly dissolved peptide. Morphology was evaluated electron microscopy. Gene expression analyzed...
To investigate the mechanism by which human islet amyloid polypeptide (hIAPP) fibril formation results in calcium influx across plasma membrane of pancreatic beta cells, and its association with apoptosis. Cytoplasmic intracellular concentrations ([Ca2+]i) were monitored for 2 h as 340/380 nm fluorescence ratio fura-2 loaded cells MIN6 mouse cell line. Cell morphology was evaluated transmission electron microscopy, viability FACS. hIAPP (10 μmol/l) increased [Ca2+]i 21% standard buffer, 8%...